Business Description
Ablynx NV
SIC : 2836
ISIN : BE0005620910
Compare
Compare
Traded in other countries / regions
4AYB.Germany Description
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.42 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | -0.91 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 8.67 | |||||
| Beneish M-Score | -3.06 | |||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.5 | |||||
| 3-Year EBITDA Growth Rate | -93.6 | |||||
| 3-Year EPS without NRI Growth Rate | -90.9 | |||||
| 3-Year FCF Growth Rate | -13.6 | |||||
| 3-Year Book Growth Rate | 19.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.48 | |||||
| Quick Ratio | 3.48 | |||||
| Days Sales Outstanding | 13.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.4 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -96.71 | |||||
| Net Margin % | -195.33 | |||||
| ROE % | -89.61 | |||||
| ROA % | -36.51 | |||||
| ROC (Joel Greenblatt) % | -2629.75 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 50.47 | |||||
| PB Ratio | 18.7 | |||||
| EV-to-EBIT | -32.61 | |||||
| EV-to-EBITDA | -33.62 | |||||
| EV-to-Revenue | 59.35 | |||||
| Earnings Yield (Greenblatt) % | -3.07 | |||||
| FCF Yield % | -1.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ablynx NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.65 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 6.6 - 10.18 | ||
| Shares Outstanding (Mil) | 43.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ablynx NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ablynx NV Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ablynx NV Frequently Asked Questions
What is Ablynx NV(XBRU:ABLXS)'s stock price today?
The current price of XBRU:ABLXS is €0.00. The 52 week high of XBRU:ABLXS is €10.18 and 52 week low is €6.60.
When is next earnings date of Ablynx NV(XBRU:ABLXS)?
The next earnings date of Ablynx NV(XBRU:ABLXS) is .
Does Ablynx NV(XBRU:ABLXS) pay dividends? If so, how much?
Ablynx NV(XBRU:ABLXS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers